Specialty Generics – FAQs for Customers of the Specialty Generics Business

About the Proposed Global Settlement

1. What did Mallinckrodt announce?
   - We reached an agreement in principle on the terms of a global settlement that would resolve all opioid-related claims against Mallinckrodt, Specialty Generics, and the Company’s other subsidiaries.
   - The agreement in principle is with a court-appointed plaintiffs’ executive committee representing the interests of thousands of plaintiffs in the opioid multidistrict litigation¹, and is supported by a broad-based group of 47 state and U.S. Territory Attorneys General.
   - To implement the proposed settlement, we expect that Specialty Generics, which manufactures certain generic opioid products, among other products, will file voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the coming months.
   - The Specialty Brands business and related subsidiaries would not be part of the Chapter 11 process.

2. What are the terms of the proposed settlement?
   - Under the terms of the proposed settlement, which would become effective upon Specialty Generics’ emergence from a contemplated Chapter 11 process, subject to court approval and other conditions:
     - Plaintiffs would receive $1.6 billion, comprising $300 million upon Specialty Generics’ emergence from Chapter 11 and $1.3 billion in structured increments over eight years, beginning upon effectiveness of the settlement. The substantial majority of those payments are expected to be contributed to a trust which, among other things, would establish an abatement fund to be administered to cover the costs of opioid-addiction treatment and related efforts;
     - Upon Specialty Generics’ emergence from the contemplated Chapter 11 process, the trust would receive warrants, exercisable at $3.15 per share, to purchase ordinary shares that would represent approximately 19.99% of the Company’s fully diluted outstanding shares, including after giving effect to the exercise of the warrants; and
     - Specialty Generics would abide by certain agreed-upon operating covenants.
   - Detailed terms of the proposed settlement have been filed in an 8-K with the Securities and Exchange Commission.

3. What is Chapter 11?
   - Chapter 11 is a court-supervised process that provides us the legal tools to implement the proposed settlement while our operations continue as normal.
   - Many well-known companies, including American Airlines and General Motors, have gone through a Chapter 11 process.
   - We expect the Specialty Generics business will continue operating as normal during and after the contemplated court-supervised process.

¹ Captioned In re National Prescription Opiate Litigation, Case No. 17-md-2804 (N.D. Ohio).
Specialty Generics – FAQs for Customers of the Specialty Generics Business

4. Why is Specialty Generics contemplating filing for Chapter 11?
   - We intend for Specialty Generics to file for Chapter 11 to implement the proposed global opioid settlement.
   - This court-supervised process is expected to lead to the creation of a trust which, among other things, would establish an abatement fund to offset the expense of helping to combat opioid addiction and providing support to communities impacted by opioid abuse.
   - This process would also provide a fair, orderly, efficient and legally binding mechanism to resolve all opioid-related claims against Mallinckrodt, Specialty Generics, and the Company's other subsidiaries.
   - We expect that the Specialty Generics business would continue operating as normal through a court-supervised process. The Specialty Brands business is not expected to be part of the Chapter 11 process and would continue operating as normal too.

5. Will the Company continue operating as normal if Specialty Generics files for Chapter 11?
   - We fully expect that the Specialty Generics business would continue operating as normal during and after a court-supervised process.
   - The Specialty Brands business would not be part of the Chapter 11 filing and is fully expected to continue operating normally.

6. What would Specialty Generics look like post-emergence? Would it still be a part of Mallinckrodt?
   - We currently expect that Specialty Generics will continue to be a fully operational, indirect, wholly owned subsidiary of Mallinckrodt plc during and following emergence from the contemplated court-supervised process.
   - As you may know, one of our longstanding strategic priorities has been to facilitate a separation of Specialty Generics and Specialty Brands.
   - Once Specialty Generics completes the contemplated Chapter 11 process, we will continue to evaluate strategic options for this business.
   - Looking ahead, we will continue to focus on our business operations and ensuring both the Specialty Brands and Specialty Generics businesses continue to deliver value to the Company and our stakeholders.
   - In the meantime, we remain focused on improving the lives of patients through our unwavering commitment to manufacturing and delivering high-quality generics medications and active pharmaceutical ingredients with outstanding service and integrity.

7. What are the Company’s next steps?
   - We are continuing to engage with the plaintiffs group to finalize the details and satisfy the terms of the agreement in principle.
   - Following that, we expect the filing to occur in the coming months.
   - Although there is not a definitive timeline to share, it is our intent to move through this process as quickly and efficiently as possible.
   - We will keep you informed of important milestones as we move forward.
Specialty Generics – FAQs for Customers of the Specialty Generics Business

What This Means for Customers

8. What does this mean for Specialty Generics customers?
   • We are operating as normal and fully expect to continue operating in the ordinary course during and after the contemplated court-supervised process.
   • There is no change to how we work with you, and we intend to continue supporting you as we do today.
   • We are committed to continuing to work closely with you so we can achieve our mutual goals of delivering better health outcomes.
   • We are continuing to meet our financial commitments and execute on our strategic priorities as usual. That means we remain focused on providing patient access to quality medicine in complex markets and improving the lives of patients with high-quality generics medications and active pharmaceutical ingredients.
   • We will keep you informed as we move forward. Thank you for your continued support.

9. Will you continue to fulfill orders?
   • Yes. There is no change to how we work with you, and we intend to continue supporting you as we do today.
   • We will keep you informed as we move forward. Thank you for your continued support.

10. Will my Company contacts remain the same?
    • Yes.

About the Debt Refinancing Activities

11. What are the debt refinancing activities you announced?
    • We entered into certain agreements relating to potential financing and debt exchange transactions definitive agreements with certain of our credit agreement lenders and senior noteholders under which those parties would provide a new $800.0 million term loan to address near term debt maturities.
    • We intend to use the proceeds to redeem our senior notes due April 2020, pay fees and expenses associated with the refinancing activities, and partially repay the Company’s revolving credit facility, extending the revolver maturity to March 2024.
    • We expect these refinancing activities, if implemented, will provide us with the flexibility in the near term as we work to complete the opioid settlement.

12. Why is the Company undertaking these debt refinancing activities?
    • Reducing our debt and strengthening our financial position continue to be key priorities.
    • While we are continuing to generate significant cash flows, we expect these refinancing activities, if implemented, to provide us with additional financial flexibility in the near term as we work to complete the opioid settlement.
About the Company’s Fourth Quarter and Full-Year 2019 Earnings

13. How is the overall business performing?
   • We are pleased with the operating strength of the business as we finished 2019.
   • Our fourth quarter and full-year 2019 results reflect the continued strength of both our Brands and Generics businesses and underscore our vision for the future.
   • We have also continued to make progress against the strategic priorities we outlined at the beginning of the year, including maximizing the value of our diversified in-line portfolio, advancing our pipeline and executing disciplined capital allocation.

Additional Information

14. How can I obtain more information?
   • We will keep you informed as we move forward.
   • We have also created a website with information specific to the proposed settlement, which you can visit at www.advancingmnk.com.
   • If you have any further questions, please do not hesitate to reach out to your normal company contact.